twitter
en POLSKI
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2017
vol. 119
 
Share:
Share:
abstract:
Original paper

The effect of vascular endothelial growth factor VEGF-A gene polymorphisms and intravitreal anti-VEGF treatment outcomes in patients with exudative age-related macular degeneration

Agnieszka Kubicka-Trząska
1
,
Izabella Karska-Basta
1
,
Sylwia Dziedzina
2
,
Marek Sanak
2
,
Bożena Romanowska-Dixon
1

  1. Klinika Okulistyki i Onkologii Okulistycznej Katedry Okulistyki Uniwersytetu Jagiellońskiego Collegium Medicum w Krakowie
  2. Zakład Biologii Molekularnej i Genetyki Klinicznej II Katedry Chorób Wewnętrznych Uniwersytetu Jagiellońskiego Collegium Medicum w Krakowie
Online publish date: 2017/11/29
View full text Get citation
 
PlumX metrics:
Aim
To analyse the correlation between the rs2146323 and rs699947 polymorphisms of VEGF-A gene and the risk of age-related macular degeneration and response to anti-VEGF therapy in affected patients.

Material and methods
106 patients with exudative age-related macular degeneration treated with intravitreal ranibizumab or bevacizumab were enrolled. Treatment response was assessed at 4-week intervals for 6 months and was based on the best corrected visual acuity and central retinal thickness compared to the baseline status. The control group included 60 subjects without age-related macular degeneration. Genetic testing (TaqMan Applied Biosystems) was performed in all cases.

Results
There was no correlation between the rs2146323 polymorphism of VEGF-A gene and age-related macular degeneration; yet, there was a correlation between this polymorphism and anti-VEGF treatment outcomes. Patients with CC genotype of rs2146323 VEGF-A polymorphism demonstrated significantly better treatment response. At the end of a follow-up, age-related macular degeneration patients with positive CC genotype of rs2146323 VEGF-A gene polymorphism had final better best corrected visual acuity and showed significant central retinal thickness reduction as compared to individuals negative for this genotype (OR = 2.65, 95% CI (1.17–5.99); p = 0.0171). Among the 25.47% of “non-responders”, genotype CC of rs2146323 VEGF-A was present in 28.85% of cases, while genotype AC was detected in 61.54% of cases (p = 0.0128). There was no correlation between rs699947 VEGF-A polymorphism and either age-related macular degeneration or response to anti-VEGF treatment.

Conclusions
The study showed that rs2146323 and rs699947 VEGF-A polymorphisms are not associated with increased risk of age-related macular degeneration. However, the rs2146323 VEGF-A polymorphism modulated the response to anti-VEGF therapy. Genotype CC of rs2146323 was associated with an improved response to anti-VEGF treatment, while patients with genotype AC of rs2146323 showed worse functional and anatomical response to anti-VEGF agents.

keywords:

vascular endothelial growth factor, genetic polymorphism, age-related macular degeneration

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.